These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33171342)

  • 1. Pharmacokinetics, tolerability, and clinical effectiveness of perampanel in Japanese patients with epilepsy.
    Yamamoto Y; Shiratani Y; Asai S; Usui N; Nishida T; Imai K; Kagawa Y; Takahashi Y
    Seizure; 2020 Dec; 83():181-186. PubMed ID: 33171342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
    Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M
    Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Drug Monitoring for Perampanel in Japanese Epilepsy Patients: Influence of Concomitant Antiepileptic Drugs.
    Yamamoto Y; Usui N; Nishida T; Takahashi Y; Imai K; Kagawa Y; Inoue Y
    Ther Drug Monit; 2017 Aug; 39(4):446-449. PubMed ID: 28703720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Monitoring of Lacosamide in Japanese Patients With Epilepsy: Clinical Response, Tolerability, and Optimal Therapeutic Range.
    Yamamoto Y; Terada K; Araki Y; Fukushima Y; Imai K; Kagawa Y; Takahashi Y
    Ther Drug Monit; 2020 Oct; 42(5):754-759. PubMed ID: 32941398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis.
    Glauser T; Laurenza A; Yang H; Williams B; Ma T; Fain R
    Epilepsy Res; 2016 Jan; 119():34-40. PubMed ID: 26656783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
    Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
    Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy.
    Gidal BE; Laurenza A; Hussein Z; Yang H; Fain R; Edelstein J; Kumar D; Ferry J
    Neurology; 2015 May; 84(19):1972-80. PubMed ID: 25878177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
    Gidal BE; Ferry J; Majid O; Hussein Z
    Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perampanel Serum Concentrations in Adults With Epilepsy: Effect of Dose, Age, Sex, and Concomitant Anti-Epileptic Drugs.
    Patsalos PN; Gougoulaki M; Sander JW
    Ther Drug Monit; 2016 Jun; 38(3):358-64. PubMed ID: 26727625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in serum perampanel concentration profile after discontinuation of carbamazepine.
    Murugesu S; Okayama K; Yamamoto Y; Terada K; Takahashi Y
    Epileptic Disord; 2020 Aug; 22(4):455-461. PubMed ID: 32782230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Drug Monitoring for Rufinamide in Japanese Patients With Epilepsy: Focus on Drug Interactions, Tolerability, and Clinical Effectiveness.
    Yamamoto Y; Inoue Y; Usui N; Imai K; Kagawa Y; Takahashi Y
    Ther Drug Monit; 2022 Aug; 44(4):585-591. PubMed ID: 35213526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs.
    Markoula S; Teotonio R; Ratnaraj N; Duncan JS; Sander JW; Patsalos PN
    Ther Drug Monit; 2014 Aug; 36(4):494-8. PubMed ID: 24562047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.
    Kwan P; Brodie MJ; Laurenza A; FitzGibbon H; Gidal BE
    Epilepsy Res; 2015 Nov; 117():117-24. PubMed ID: 26448264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of therapeutic drug level monitoring of phenobarbital, phenytoin and carbamazepine in Iranian epileptic patients.
    Babaei A; Eslamai MH
    Int J Clin Pharmacol Ther; 2007 Feb; 45(2):121-5. PubMed ID: 17323792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect and tolerability of perampanel in patients with drug-resistant epilepsy.
    Lossius IMB; Svendsen T; Sødal HF; Kjeldstadli K; Lossius MI; Nakken KO; Johannessen Landmark C
    Epilepsy Behav; 2021 Jun; 119():107965. PubMed ID: 33940525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
    Contin M; Riva R; Albani F; Avoni P; Baruzzi A
    Ther Drug Monit; 2002 Jun; 24(3):332-7. PubMed ID: 12021622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON).
    Abril Jaramillo J; Estévez María JC; Girón Úbeda JM; Vega López Ó; Calzado Rivas ME; Pérez Díaz H; García Martín G; Vila Herrero E; Chamorro-Muñoz M; Vázquez F; De la Fuente C; Redondo L; Peláez N; Santágueda P; Rodríguez Uranga JJ
    Epilepsy Behav; 2020 Jan; 102():106655. PubMed ID: 31812902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of mono- and add-on perampanel in pediatric patients with epilepsy: Experience from a single-center retrospective study.
    Li Y; Guo HL; Hu YH; Wang J; Zhang YY; Huang J; Xu J; Chen J; Lu XP; Chen F
    Epilepsia Open; 2024 Feb; 9(1):268-277. PubMed ID: 37943144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Inflammation on the Pharmacokinetics of Perampanel.
    Yamamoto Y; Takahashi Y; Horino A; Usui N; Nishida T; Imai K; Kagawa Y; Inoue Y
    Ther Drug Monit; 2018 Dec; 40(6):725-729. PubMed ID: 30086086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy.
    Yamamoto Y; Takahashi Y; Imai K; Takahashi M; Nakai M; Inoue Y; Kagawa Y
    Eur J Clin Pharmacol; 2014 Oct; 70(10):1203-10. PubMed ID: 25048408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.